Hot Performing Stocks To Buy For 2014

These days, small caps are outperforming large caps–and that’s true among individual stocks, as well as the index level.

The SPDR S&P 500 ETF (SPY) has gained 1.1% during the past three months, to the iShares Russell 2000 ETF’s (IWM) 5.9% gain. McDonald’s (MCD), meanwhile, has dropped 4.9% during that time frame, while�Burger King (BKW) has jumped 6.8%

Jonathan Krinsky, chief technical market analyst at Miller Tabak, expects Burger King to continue to outperform McDonald’s. He writes:

Burger King is a newer IPO, but has shown a very constructive pattern as it has respected the uptrend line since the low made last August. After breaking out to new highs this June, it has been consolidating in a symmetrical triangle. RSI has held above 50, and we think odds favor a breakout to the upside, which would target the $22 area…

Since that all time high of 103.70, MCD has been making lower highs, while testing the $95 support level. With RSI unable to get much above 50 on recent rallies, and the 50 DMA declining, the stock now looks vulnerable to further downside. The pattern since March of this year is an ascending triangle, which has a measured move down to the $87 level.

Hot Logistics Stocks To Invest In Right Now: DRDGOLD Ltd (DRD)

DRDGOLD Limited (DRDGOLD), incorporated on February 16, 1895, is a South Africa-based surface gold retreatment company. DRDGOLD operates in a single segment, Ergo. Ergo is a surface retreatment operation and treats old slime and sand dumps to the south of Johannesburg�� central business district, as well as the east and central Rand goldfields. The operation consists of four plants: Brakpan, Crown, City and Knights. Included in the Ergo segment is the East Rand Proprietary Mines Limited (ERPM) surface operation comprise the Cason retreatment operation. Ergo is evaluating the viability of processing surface uranium- and sulphur-bearing tailings on the east and central Rand goldfields of South Africa. The Company�� business includes Crown Gold Recoveries (Pty) Limited (Crown), Ergo Mining (Pty) Limited (Ergo JV) and ErgoGold are jointly referred to as ERGO and ERPM. On June 1, 2012, the Company disposed of its 74% interest in and loan claims against Blyvoor.

The Company�� focus is on the recovery of lower-risk, lower-cost, higher-margin ounces. As of October 9, 2012, 68% of production comes from surface retreatment operation. The company holds a 74%-interest in operating subsidiary Ergo Mining Operations (Proprietary) Limited. Crown is the gold surface tailings retreatment facility, reprocessing the large and numerous sand and slimes dumps along the reefs that stretch from east to west just to the south of Johannesburg�� central business district (CBD). Crown�� major project is Top Star, a tailings dam to the south of Johannesburg�� CBD. ERPM is situated on the Witwatersrand Basin near the town of Boksburg, 25 kilometers to the east of Johannesburg. The Ergo as a joint venture between DRDGOLD and Mintails Limited. Wholly owned by the DRDGOLD group, Ergo has a network of surface rights that provide access to a further 600 million tons of surface tailings deposited across the western, central and eastern Witwatesrand. Ergo has three tailings deposition facilities. ERPM continues ! as a surface retreatment operation. It holds 65% of ErgoGold through the contribution of its Elsburg Tailings Complex.

Advisors' Opinion:

• [By Luke Jacobi]

  Moving opposite of technology, basic materials shares rose 0.19 percent in trading on Friday. Top gainers in the sector included DRDGOLD (NYSE: DRD), up seven percent, and LyondellBasell Industries NV (NYSE: LYB), up 4.3 percent.

• [By Garrett Cook]

  Basic materials shares gained 0.10 percent in trading on Friday. Meanwhile, top gainers in the sector included DRDGOLD (NYSE: DRD), up 7.4 percent, and LyondellBasell Industries NV (NYSE: LYB), up 4.5 percent.

Hot Performing Stocks To Buy For 2014: Alumina Ltd (AWC)

Alumina Limited, through its 40% equity interest in Alcoa World Alumina and Chemicals, engages in the bauxite mining, alumina refining, and aluminum smelting businesses. It has interests in eight alumina refineries and eight bauxite mines, as well as operates two aluminum smelters in Victoria, Australia. The company also owns interests in a network of mines, refineries, and smelters in the United States, Guinea, Suriname, Jamaica, Brazil, and Spain. In addition, it owns and operates a shipping operation that transports alumina, aluminum, and raw materials worldwide. The company, formerly known as WMC Limited, was founded in 1970 and is based in Southbank, Australia.

Advisors' Opinion:

• [By Tim Melvin]

  One such company is Alumina Limited (NYSE ADR: AWC), an Australian aluminum company.

  Alumina, which mines and refines aluminum, operates eight refineries and two aluminum smelters and owns or has interest in seven mining operations. It has a shipping operation that transports aluminum-related raw materials.

• [By Ben Levisohn]

  Shares of Alcoa have dropped 3.3% to $7.90 today at 9:30 a.m. The downgrade has also hit other aluminum producers this morning. Alumina (AWC) has fallen 1.1% to $3.73, Kaiser Aluminum (KALU) has declined 0.7% to $71.17, and BHP Billiton (BHP), of which aluminum is but a small piece, is off 0.3% at $66.22.

• [By Peter Krauth]

  Prospects are strong, as AA continues to push productivity gains and further penetrate sectors like aerospace and automotive. As automobiles look to improve fuel consumption, the average U.S. car will likely go from about 14 lbs. to 55 lbs. of aluminum in just the next three years. Alcoa CEO Klaus Kleinfeld thinks cars will contain 135 lbs. of aluminum within twelve years.

  The Even Better-Looking Sister Is... Another way to play aluminum might be through Alumina Ltd. (ADR) (NYSE: AWC).

  Alumina owns 40% of the world's largest alumina business, Alcoa World Alumina and Chemicals (AWAC), with Alcoa owning and managing the other 60%.

Hot Performing Stocks To Buy For 2014: Alexza Pharmaceuticals Inc.(ALXA)

Alexza Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, and commercialization of novel proprietary products for the acute treatment of central nervous system conditions worldwide. Its product candidates are based on a proprietary technology, the Staccato system, which vaporizes an excipient-free drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery. The company?s lead product candidate includes ADASUVE (Staccato loxapine) for the acute treatment of agitation in adults with schizophrenia or bipolar disorder. Its other product candidates under development comprise AZ-007 (Staccato zaleplon), which has completed Phase I clinical trials for the treatment of insomnia; and Staccato nicotine that is in pre-Phase 1 clinical trials to help smokers quit by addressing both the chemical and behavioral components of nicotine addiction by delivering nicotine replacement through inhalation. The company was f ormerly known as Alexza Molecular Delivery Corporation and changed its name to Alexza Pharmaceuticals, Inc. in July 2005. Alexza Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Mountain View, California.

Advisors' Opinion:

• [By Monica Wolfe]

  Alexza Pharmaceuticals (ALXA)

  As Alexza Pharmaceuticals��price has continued to stay at a 10-year low price, President and CEO Thomas King decided to increase his holdings in the company.

• [By Edison Investment Research]

  Alexza's (ALXA) US marketing deal with Teva (TEVA) for Adasuve (orally-inhaled loxapine) enhances the product's US sales prospects given Teva's expertise in the psychiatric and hospital markets. Adasuve is a potentially disruptive new product for acute agitation in schizophrenia or bipolar disorder, given its advantages over existing options (injection/oral/buccal). The investment case is shifting from a development/regulatory play to one of commercial execution by Adasuve's licensees, Teva in the US and Ferrer in Europe.

Hot Performing Stocks To Buy For 2014: The Navigators Group Inc.(NAVG)

The Navigators Group, Inc., together with its subsidiaries, engages in underwriting ocean marine, property and casualty, professional liability, and specialty insurance products and services. The company?s marine and inland marine insurance products include marine and energy liability, cargo, craft/fishing vessel, bluewater hull, brownwater hull, protection and indemnity, war, customs bonds, commercial output policy, construction, transportation, specialty, specie, and marine excess-of-loss reinsurance Its property and casualty insurance products comprise general and environmental liability, umbrella and excess, offshore energy, onshore energy, operational engineering, construction, life sciences, exporters package liability, accident and health reinsurance, Latin America property and casualty reinsurance, agriculture reinsurance, professional liability reinsurance, bloodstock, and the U.S. casualty insurance products. The company?s professional liability products inclu de directors and officers, employment practices, fiduciary, crime, accountants professional, lawyers professional, insurance agent errors and omissions, miscellaneous professional, technology and media, design professionals, and real estate agent liability insurance products. The Navigators Group, Inc. distributes its products through global, national, and regional retail and wholesale insurance brokers. The company was founded in 1981 and is based in Rye Brook, New York.

Advisors' Opinion:

• [By CRWE]

  The Navigators Group, Inc. (NASDAQ:NAVG) reported that its principal underwriting agency subsidiary, Navigators Management Company, Inc., has expanded Adrien T. Robinson’s responsibilities to include the open-brokerage products of Life Sciences, Global Package, Environmental Casualty, Commercial Auto and Excess Casualty Retail. Mr. Robinson was previously President of the Environmental Casualty division.

• [By Ben Levisohn]

  Tower Group has dropped 12% to $3.88 today at 11:39 a.m., while Stewart Information Services (STC) has dipped 0.1% to $31.16, the�Navigators Group�(NAVG) has fallen 1.4% to $54.78 and HCI Group�(HCI) has gained 1% to $38.16.

• [By Ben Levisohn]

  Tower Group has dropped 40% to $4.43 today, and some other small insurers are also getting dinged this morning. HCI Group (HCI) has fallen 1.8% to $39.36, Stewart Information Services (STC) has declined 0.7% to $31.36 and the Navigators Group (NAVG) has ticked down 0.4% to $56.10.

Hot Performing Stocks To Buy For 2014: Oncolytics Biotech Inc (ONCY)

Oncolytics Biotech Inc. (Oncolytics), incorporated on April 2, 1998, is a development-stage company. The Company is focused on its research and development of REOLYSIN, which is its cancer therapeutic. REOLYSIN is developed from the reovirus. This virus has been demonstrated in tumour cells bearing an activated Ras pathway. Oncolytics is directing a clinical trial program with the focus of developing REOLYSIN as a human cancer therapeutic. The clinical program includes clinical trials, which it sponsors directly along with Third Party Clinical Trials. Third Party Clinical Trials are clinical trials that are being sponsored by other institutions. As of December 31, 2011, the United States National Cancer Institute (NCI), the University of Leeds and the Cancer Therapy & Research Center at the University of Texas Health Center in San Antonio (CTRC) were sponsoring part of its clinical trial program.

The Company�� clinical trial program has included human trials using REOLYSIN alone, and in combination with radiation and chemotherapy, and delivered via local administration and/or intravenous administration. Oncolytics uses contract toll manufacturers to produce REOLYSIN. On December 31, 2011, the Company had two wholly owned subsidiaries, Oncolytics Biotech (Barbados) Inc. (OBB) and Valens Pharma Ltd. Oncolytics Biotech (US) Inc. and Oncolytics Biotech (U.K.) are wholly owned subsidiaries of OBB.

Advisors' Opinion:

• [By Maxx Chatsko]

  T-VEC is not your traditional biologic drug. It is actually a bioengineered form of the herpes virus that, once injected into cancerous tumors, replicates, and produces an immune-stimulating protein that puts a bulls eye on cancer cells throughout the body. Despite its promise and intriguing mechanism of action, T-VEC is not in further development at Amgen. However, Oncolytics (NASDAQ: ONCY  ) has shown promising results for its bioengineered form of reovirus called Reolysin. Initial phase 3 results showed that 86% of patients taking the drug had reduced tumor mass or growth after six weeks of treatment. �

• [By Sean Williams]

  With this in mind, I feel it'd be prudent of biotech-savvy investors to give Oncolytics Biotech (NASDAQ: ONCY  ) a closer look.

  The big risks
  I'm quite aware that there are a lot factors that'd raise a red flag with Oncolytics. Similar to Affymax, you could say that Oncolytics has put all of its eggs in one basket with its lead experimental drug, reolysin. According to Oncolytics' website, including its U.K., Canadian, and U.S. studies, reolysin as either a monotherapy or combination therapy is the basis for all 31 clinical trials! Obviously, if reolysin proves ineffective or unsafe, Oncolytics is going to be a world of hurt.

Hot Performing Stocks To Buy For 2014: DUSA Pharmaceuticals Inc.(DUSA)

DUSA Pharmaceuticals, Inc., a vertically integrated dermatology company, develops and markets Levulan photodynamic therapy (PDT) and other products for common skin conditions primarily in the United States, Canada, and Korea. Its products include Levulan Kerastick 20% Topical Solution with PDT and the BLU-U brand light source for the treatment of non-hyperkeratotic actinic keratoses of the face or scalp. The company also markets the BLU-U without Levulan for the treatment of moderate inflammatory acne vulgaris and general dermatological conditions; and non-PDT drug products, such as ClindaReach and AVAR products. DUSA Pharmaceuticals, Inc. was founded in 1991 and is based in Wilmington, Massachusetts.

Advisors' Opinion:

• [By CRWE]

  DUSA Pharmaceuticals, Inc.(r) (Nasdaq:DUSA), a dermatology company that is developing and marketing Levulan(r) Photodynamic Therapy (PDT), reported that Bob Doman, President and Chief Executive Officer, will present a corporate overview at the Rodman & Renshaw 14th Annual Healthcare Conference on Monday, September 10, 2012 at 11:15 a.m. ET at The Waldorf Astoria Hotel in New York City.